Alvotech, a global biotech company, has announced a new supply and commercialization agreement with Advanz Pharma for AVT10, their biosimilar candidate to Cimzia® (certolizumab pegol). This marks a significant step as it is the only biosimilar referencing Cimzia® currently under development worldwide. The reference product, Cimzia®, is widely used for treating chronic rheumatic diseases, particularly among women of childbearing age. The agreement aims to expand access to high-quality biologics for patients in Europe and is a continuation of the strategic partnership between Alvotech and Advanz Pharma. The companies plan to launch their first biosimilars in Europe in the fourth quarter of 2025. Cimzia® achieved worldwide sales of $2.3 billion in 2024.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。